Genenta Science srl

The positive Phase III results and subsequent US approval of lecanemab for Alzheimer’s disease was reflected by a spike in enthusiasm for the central nervous system (CNS) space among the 90 or so resp

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and

“Biomedical innovation is at its golden age, and scientific innovation will continue to be strong,” declared Søren Møller , managing partner at Novo Seeds , the life science start-up financing arm o

The biopharmaceutical initial public offering pace has picked back up in the US again with five new offerings so far in December, but all of the IPOs were launched by firms that raised relatively smal